ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 212 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q2 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $44,374 | -21.6% | 8,142 | -3.4% | 0.00% | – |
Q2 2023 | $56,579 | -6.4% | 8,432 | +23.2% | 0.00% | – |
Q1 2023 | $60,442 | +14.9% | 6,845 | -0.6% | 0.00% | – |
Q4 2022 | $52,609 | -17.8% | 6,886 | -22.4% | 0.00% | – |
Q3 2022 | $64,000 | +100.0% | 8,876 | +127.6% | 0.00% | – |
Q2 2022 | $32,000 | -56.2% | 3,899 | -26.3% | 0.00% | – |
Q1 2022 | $73,000 | +37.7% | 5,293 | +176.7% | 0.00% | – |
Q4 2021 | $53,000 | -70.4% | 1,913 | -63.5% | 0.00% | – |
Q3 2021 | $179,000 | -43.2% | 5,246 | -32.0% | 0.00% | – |
Q2 2021 | $315,000 | -19.8% | 7,718 | -20.9% | 0.00% | – |
Q1 2021 | $393,000 | -33.2% | 9,760 | -1.7% | 0.00% | -100.0% |
Q4 2020 | $588,000 | +90.3% | 9,924 | +56.0% | 0.00% | – |
Q3 2020 | $309,000 | -4.0% | 6,362 | -4.1% | 0.00% | – |
Q2 2020 | $322,000 | +1688.9% | 6,635 | +922.3% | 0.00% | – |
Q1 2020 | $18,000 | -5.3% | 649 | +1.7% | 0.00% | – |
Q4 2019 | $19,000 | -5.0% | 638 | -0.5% | 0.00% | – |
Q3 2019 | $20,000 | – | 641 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 3,030,434 | $20,334,212 | 13.72% |
BERYLSON CAPITAL PARTNERS, LLC | 228,000 | $1,529,880 | 4.32% |
Eagle Health Investments LP | 1,214,860 | $8,151,711 | 1.52% |
Matrix Capital Management Company, LP | 11,572,590 | $77,652,079 | 0.90% |
Triatomic Management LP | 121,166 | $813,024 | 0.83% |
VIKING GLOBAL INVESTORS LP | 29,993,708 | $201,257,781 | 0.82% |
Aristotle Atlantic Partners, LLC | 3,104,961 | $20,834,288 | 0.78% |
Pier Capital, LLC | 737,589 | $4,949,222 | 0.71% |
ARK Investment Management | 10,453,752 | $70,144,675 | 0.46% |
Nikko Asset Management Americas, Inc. | 6,384,047 | $42,773,115 | 0.45% |